Feedback
Purkinje Cell Cytoplasmic Antibody by IFA with Reflex to Titer & Immunoblot  (INACTIVE as of 5/20/13.  Refer to 2007961)
0059444
Ordering Recommendation
Mnemonic
PCCA R
Methodology
Semi-Quantitative Indirect Fluorescent Antibody/Qualitative Immunoblot
Performed
Wed
Reported
1-9 days
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
ARUP Consult®
Disease Topics
Specimen Required
Patient Preparation
 
Collect
Serum separator tube. 
Specimen Preparation
Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.5 mL) 
Storage/Transport Temperature
Frozen. 
Unacceptable Conditions
Plasma. Contaminated, heat-inactivated, hemolyzed, or lipemic specimens. 
Remarks
 
Stability
After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year 
Reference Interval
Components
Reference Interval
Purkinje Cell Cytoplasmic Ab (PCCA or PCA-1) ScreenLess than 1:10
Purkinje Cell Cytoplasmic Ab (PCCA or PCA-1) Titer< 1:10
Purkinje Cell Cytoplasmic Ab (PCCA or PCA-1) ImmunoblotNegative

Interpretive Data
There is a strong association among paraneoplastic syndromes, anti-neuronal antibody specifications and the associated tumor type. However, in a minority of patients with paraneoplastic syndrome with anti-neuronal antibodies, no tumor may be found. Certain patients with paraneoplastic syndromes may not have detectable levels (by IFA) of anti-neuronal antibodies. Most cases that develop PCD in association with Hodgkin's disease, non-SCLC, gastrointestinal carcinomas do not have demonstrable anti-Yo antibodies. There also exist anti-Yo negative but atypical anti-Purkinje cell cytoplasm autoantibodies (atypical APCA's). Such antibodies can occur in association with Hodgkin's disease, adenocarcinoma of the lung, colon, or prostate. 5-6% patients with ovarian cancer have circulating anti-Yo or anti-Ri antibodies in the absence of any paraneoplastic neurological syndromes.

Compliance Statement D: This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Note
If Purkinje cell screen is  1:10, then a titer and immunoblot will be added. Additional charges apply.
CPT Code(s)
86255; if reflexed, add 86256; 83516
Components
Component Test Code*Component Chart NameLOINC
0059440Purkinje Cell Ab Screen, RFLX14249-7
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • Hu, Yo, and Ri Antibodies with Reflex to Titers and Western Blot (Purkinje Cell Cytoplasmic Antibody
  • PCA (Purkinje Cell Cytoplasmic Antibody by IFA with Reflex to Titer & Immunoblot)
  • PCCA (Purkinje Cell Cytoplasmic Antibody by IFA with Reflex to Titer & Immunoblot)
  • Yo Antibody (Purkinje Cell Cytoplasmic Antibody by IFA with Reflex to Titer & Immunoblot)